2017 American Transplant Congress
Daratumumab for Severe Refractory Proliferative Glomerulonephritis with Monoclonal Immune Deposits (PGNMID).
Introduction-We report as case of refractory PGNMID treated succesfully with anti-CD38 antibody (Daratumumab). Case report-65 year old male with ESRD attributed to to post infectious…2017 American Transplant Congress
Does Blockade of ICOS/ICOS-L Pathway Act Synergistically with αCD40 Costimulation Pathway Blockade?
University of Maryland School of Medicine, Baltimore, MD
Purpose: Inducible costimulator (ICOS) on T cells enhances basic T cell responses to foreign antigen, and increased ICOS expression is detected in association with pathogenic…2017 American Transplant Congress
Delayed Calcineurin Inhibitor Introduction and Long Term Renal Outcomes in Liver Transplant Recipients Receiving Basiliximab Induction.
BACKGROUND Basiliximab may be used to delay the initation of calcineurin inhibitors (CNI) in patients with renal injury after liver transplantation (LT). The optimal time…2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…2016 American Transplant Congress
Establishing the Relationship Between Receptor Occupancy, Serum Exposure and Pathway Inhibition by the Blocking, Non-Depleting Anti-CD40 Antibody CFZ533 to Inform Dose Selection in Clinical Transplantation.
Novartis Institutes for Biomedical Research, Basel, Switzerland.
Background. CD40-CD154 pathway blockade significantly prolongs renal allograft survival in non-human primates (NHPs), and trials of the novel blocking, non-depleting anti-CD40 monoclonal antibody (mAb) CFZ533…2016 American Transplant Congress
The Role of HLA Class II Antibody in Endothelial Cell Activation and Allograft Rejection.
Background: Antibody-mediated rejection is one of the major causes of chronic rejection. This is mediated by endothelial cell activation, a process of endothelium microvascular inflammation…2016 American Transplant Congress
The Effect of Rituximab on Hepatitis B Reactivation in Kidney Transplant Recipients with Resolved Hepatitis B.
Background: Hepatitis B virus (HBV) reactivation is a well-known complication of immunosuppressive therapy in resolved HBV (hepatitis B surface antigen [HBsAg] negative and hepatitis B…2016 American Transplant Congress
Evaluation of Conformational Diversity of a Single HLA-I Molecule Coated on Single Antigen Beads: Potential Impact on Organ Allocation?
Terasaki Foundation Laboratory, Los Angeles, CA.
Recombinant HLA-I (rHLA-I) molecules are the antigenic targets used to screen HLA-I DSA in the sera of pre- or post-transplant patients. A conformational diversity, β2-microglobulin-associated…2016 American Transplant Congress
C3 Glomerulopathy Secondary to Complement Factor H Inhibition by Monoclonal Kappa Light Chains.
Background: Monoclonal gammopathy of renal significance (MGRS) implies a causal relationship between clonal B cell proliferation and renal disease and is associated with high morbidity…2016 American Transplant Congress
Successful Prophylactic Use of Eculizumab in aHUS Kidney Transplant Patients: A Report of 9 Cases.
AHUS is a thrombotic microangiopathy (TMA) triggered by alternate complement pathway (AP) dysregulation. In 60% of patients, a pathogenic variant can be identified in one…
American Transplant Congress abstracts